Clinical trials: Acute Rejection of Renal Transplant
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
Microvascular Inflammation - MVI in Kindey Transplant Recipients
DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)
The DARA-MVI Study is a prospective, randomized, controlled, open-label trial designed to evaluate the effect of daratumumab on microvascular inflammation (MVI) in kidney transplant recipients with C4d-negative biopsies.
- Trial name
- DARA-MVI (NCT07274462)
- Testing
- DARATUMUMAB (DARZALEX®), Observation (Standard Care)
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- University Hospital, Martin
Acute Rejection of Renal Transplant, Renal Graft Loss
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients
Mycophenolate mofetil (MMF) decreases the risk of acute rejection and is associated with improved graft survival in renal transplant recipients.
- Trial name
- NCT01496703
- Testing
- no intervention, this is an observational retrospective trial
- Where
- Belgium
- Volunteers
- 749 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Transplantation
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.
- Trial name
- NCT00492869
- Testing
- AEB071
- Where
- 41 sites in United States, Belgium and 5 more
- Volunteers
- 124 people
- Sponsor
- Novartis Pharmaceuticals
Acute Rejection of Renal Transplant, Graft Failure
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function.
- Trial name
- NCT05084768
- Testing
- Donor-derived cell-free DNA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
Kidney Transplant Rejection
Tacrolimus Exposure in Kidney Transplantation
Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation.
- Trial name
- NCT06348446
- Where
- 4 sites in South Korea
- Volunteers
- 12,000 people
- Sponsor
- Seoul National University Hospital
Pediatric Kidney Transplantation
Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients
The aim of this study is assess the safety and efficacy of the treatment regimen of basiliximab ,cyclosporine microemulsion, MMF, and prednisone combined compared to cyclosporine microemulsion, MMF and prednisone in the time to…
- Trial name
- NCT00228020
- Testing
- basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent), MMF, cyclosporine, steroids
- Volunteers
- 212 people
- Sponsor
- Novartis
Renal Transplant Rejection
Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept®…
- Trial name
- IBERICA (NCT01324934)
- Testing
- ATG-Fresenius S
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Renal Transplant
24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant…
- Trial name
- EVITA (NCT01169701)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid (MPA)
- Where
- 9 sites in Spain
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
Advances in renal transplantation have increased life-expectancy in patients with end-stage kidney disease. Conventional immunosuppressive drugs prevent efficiently early allograft losses due to T-cell mediated rejection.
- Trial name
- TAMARCIN (NCT02113891)
- Testing
- Eculizumab
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft Failure, Death
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate…
- Conditions
- Graft Failure, Death, Acute Rejection of Renal Transplant, Infections
- Trial name
- SENIOR (NCT02558452)
- Testing
- Tacrolimus once daily (Advagraf)
- Volunteers
- 1,000 people
- Sponsor
- Klemens Budde
Rejection of Renal Transplant
Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry
Reliable and timely detection of acute rejections in renal transplant patients is important to preserve the graft function and to prevent premature graft failure.
- Trial name
- NCT01315067
- Where
- 8 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Hannover Medical School
Acute Rejection, Renal Transplantation
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00579592
- Testing
- Campath-1H, rituximab, myfortic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
Primary purpose of this study is to compare renal function between subjects receiving optimized dose Advagraf® over 52 weeks after kidney transplantation and subjects receiving standard dose Advagraf®.
- Trial name
- OPTIMIZE (NCT02161237)
- Testing
- Advagraf®
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc
Acute Rejection
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival.
- Trial name
- RIACT (NCT01117662)
- Testing
- Rituximab
- Where
- 14 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hannover Medical School
Kidney Transplantation
Efficacy and Safety of Sirolimus in Combination With Tacrolimus
To study the efficacy and safety of the administration of Tacrolimus in combination with Sirolimus for the prevention of acute rejection in patients after renal transplantation
- Trial name
- NCT00141804
- Testing
- Sirolimus
- Where
- Germany
- Volunteers
- 190 people
- Sponsor
- University Hospital Muenster
Kidney Transplantation
Freedom Study: Myfortic in Kidney Transplant Patients
The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
- Trial name
- NCT00101738
- Testing
- Myfortic
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 342 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant Rejection
Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients
The aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney…
- Trial name
- NCT04414735
- Testing
- Extracorporeal Photopheresis
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
END STAGE RENAL DISEASE
ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION
BACKGROUND: Non-steroid maintenance immunosuppression after transplantation can improve long-term lipid and hemodynamic profiles without severe acute rejection (AR) events that alter graft function or survival.
- Trial name
- ESWMEX001 (NCT02328222)
- Testing
- ESW group
- Where
- Mexico
- Volunteers
- 71 people
- Sponsor
- Unidad de Investigacion Medica en Enfermedades Renales